Gene therapy of liver tumors: Principles and applications

Digestion

Volumn 59, Issue SUPPL. 2, 1998, Pages 92-96

  Ruiz, Juan ^a   Qian, Cheng ^a   Prieto, Jesús ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b NONE   (Spain)

Author keywords

Adenoviruses; Cytokines; Gene therapy; Genetic diseases; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Liposomes; Liver cirrhosis; Retroviruses; Suicide genes

Indexed keywords

CYTOKINE; LIPOSOME; OLIGONUCLEOTIDE; VIRUS VECTOR;

ADENOVIRUS; CLINICAL TRIAL; CONFERENCE PAPER; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; LIVER METABOLISM; LIVER TUMOR; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE; TUMOR SUPPRESSOR GENE;

CARCINOMA, HEPATOCELLULAR; GENE THERAPY; HUMANS; LIVER NEOPLASMS;

EID: 0031852131     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051436     Document Type: Conference Paper

References (61)

1. Miller AD: Human gene therapy comes of age. Nature 1992;357:455-460.
2. Mulligan RC: The basic science of gene therapy. Science 1993;260:926-932.
3. Ledley FD: Hepatic gene therapy: Present and future. Hepatology 1993;18:1263-1273.
4. Chang AGY, Wu GY: Gene therapy: Applications to the treatment of gastrointestinal and liver diseases. Gastroenterology 1994;106:1076-1084.
5. Kovesdi I, Borugh DE, Bruder JT, Wickham TJ: Adenoviral vectors for gene transfer. Curr Opin Biotechnol 1997;8:583-589.
6. Gordon EM, Anderson WF: Gene therapy using retroviral vectors. Curr Opin Biotechnol 1995;6:611-616.
7. Ledley F: Nonviral gene therapy: The promise of genes as pharmaceutical products. Hum Gene Ther 1995;6:1129-1114.
8. Kato K, Kaneda Y, Sakurai M, Nakanishi M, Okada Y: Direct injection of hepatitis B virus DNA into liver induced hepatitis in adult rats. J Biol Chem 1991;266:22071-22974.
9. Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y: Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): Reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997;8:2133-2141.
10. Holmberg EG, Reuer QR, Geisert EE, Owens JL: Delivery of plasmid DNA to glial cells using pH-sensitive immunoliposomes. Biochem Biophys Res Commun 1994;201:888-893.
11. Marcel T, Grausz JD: The TMC worldwide gene therapy enrollment report, end 1996. Hum Gene Ther 1997;8:775-800.
12. Culver KW, Blaese RM: Gene therapy for cancer. Trends Genet 1994;10:174-178.
13. Roth JA, Cristiano RJ: Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
14. Bishop JM: Molecular themes in oncogenesis. Cell 1991;64:235-248.
15. Weimberg RA: Tumor suppressor genes. Science 1991;254:1138-1146.
16. Georges RN, Mukhopadhyay T, Zhang Y, Yen N, Roth JA: Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res 1993;53:1743-1746.
17. Kashani-Sabet M, Funato T, Florenes VA, Fodstad O, Scanlon KJ: Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res 1994;54:900-902.
18. Feng M, Cabrera G, Deshane J, Scanlon KJ, Curiel DT: Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 1995;55: 2024-2028.
19. Casalini P, Menard S, Malandrin SM, Rigo CM, Colnaghi MI, Cultraro CM, Segal S: Inhibition of tumorigenicity in lung adenocarcinoma cells by c-erbB-2 antisense expression. Int J Cancer 1997;72:631-636.
20. Ho PT, Parkinson DR: Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol 1997;24:182-202.
21. Irie A, Kijima H, Ohkawa T, Bouffard DY, Suzuki T, Curcio LD, Holm PS, Sassani A, Scanlon KJ: Anti-oncogene ribozymes for cancer gene therapy. Adv Pharmacol 1997;40:207-257.
22. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997;349: 1137-1141.
23. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994;86:1458-1462.
24. Wang J, Bucana CD, Roth JA, Zhang WW: Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther 1995;2:9-17.
25. Clayman GL, El-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ: In vivo molecular therapy with p53 for microscopic residual head and neck squamous carcinoma. Cancer Res 1995;55:1-6.
26. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996;2:985-991.
27. Moolten FL: Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1994;1:279-287.
28. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN: The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-5283.
29. Pope IM, Poston GJ, Kinsella AR: The role of the bystander effect in suicide gene therapy. Eur J Cancer 1997;33:1005-1016.
30. Freeman SM, Ramesh R, Marrogi AJ: Immune system in suicide gene therapy. Lancet 1997;249: 2-3.
31. Paillard F: Bystander effects in enzyme/prodrug gene therapy. Hum Gene Ther 1997;8:1733-1736.
32. Roth C, Rochlitz C, Kourilsky P: Immune response against tumors. Adv Immunol 1994;57: 281-351.
33. Tuting T, Storkus WJ, Lotze MT: Gene-based strategies for the immunotherapy of cancer. J Mol Med 1997;75:478-491.
34. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E: Interleukin-2 gene transfer abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-1224.
35. Restifo NP, Speiss PJ, Karp SE, Mule JJ, Rosenberg SA: A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: Correlation with antigen presentation capability. J Exp Med 1993;175:1423-1431.
36. Tahara H, Zitvogel L, Storkus WJ, Zeh HJ, McKinney TG, Schreiber RD, Gubler U, Robbins PD, Lotze MT: Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995;154:6466-6474.
37. Huang H, Chen SH, Kosai K, Finegold MJ, Woo SL: Gene therapy for hepatocellular carcinoma: Long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo. Gene Ther 1996;3:980-987.
38. Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, Woo SL, Chen SH: Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 1996;93:11302-11306.
39. Cao G, Kuriyama S, Du P, Sakamoto T, Kong X, Masui K, Qi Z: Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer. Gastroenterology 1997;112:501-510.
40. Chen L, Chen D, Block E, O'Donnell M, Kufe DW, Clinton SK: Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol 1997; 159:351-359.
41. Rakhmilevich AL, Janssen K, Turner J, Culp J, Yang NS: Cytokine gene therapy of cancer using gene gun technology: Superior antitumor activity of interleukin-12. Hum Gene Ther 1997;8: 1303-1311.
42. Galea-Lauri J, Farzaneh F, Garken J: Novel costimulators in the immune gene therapy of cancer. Cancer Gene Ther 1996;3:202-213.
43. Schuler G, Steinman RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997;186:1183-1187.
44. Wan Y, Bramson J, Carter R, Graham F, Gauldie J: Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 1997;8:1355-1363.
45. Dilloo D, Bacon K, Holden W, Zhong W, Burdach S, Zlotnik A, Brenner M: Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 1996;2:1090-1095.
46. Chen SH, Kosai K, Xu B, Pham-Nguyen K, Contant C, Finegold MJ, Woo SL: Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: Sustained antitumor immunity prolongs animal survival. Cancer Res 1996;56:3758-3762.
47. Kwong YL, Chen SH, Kosai K, Finegold M, Woo SL: Combination therapy with suicide and cytokine genes for hepatic metastases of lung cancer. Chest 1997;112:1332-1337.
48. Podda S, Ward M, Himelstein A, Richardson C, de la Flor-Weiss E, Smith L, Gottesman M, Pastan I, Bank A: Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 1992;89: 9676-9680.
49. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis AW: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of the human MDRI. Science 1992;257:99-103.
50. Harris AL, Fox S, Bicknell R, Leek R, Relf M, LeJeune S, Kaklamanis L: Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer 1994;74:1021-1025.
51. Martiny-Baron G, Marme D: VEGF-mediated tumour angiogenesis: A new target for cancer therapy. Curr Opin Biotechnol 1995;6:675-680.
52. Fan TP, Jaggar R, Bicknell R: Controlling the vasculature: Angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 1995;16:57-66.
53. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann J, Klatzmann D: Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993;90:7024-7028.
54. Qian C, Bilbao R, Bruña O, Prieto J: Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology 1995;22:118-123.
55. Qian C, Idoate M, Bilbao R, Sangro B, Bruña O, Vazquez J, Prieto J: Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. Hum Gene Ther 1997;8:349-358.
56. Arbuthnot PB, Bralet MP, Le Jossic C, Dedieu JF, Perricaudet M, Brechot C, Ferry N: In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther 1996;7:1503-1514.
57. Bao JJ, Zhang WW, Kuo MT: Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas. Hum Gene Ther 1996;7:355-365.
58. Kaneko S, Hallenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T, Anderson WF, Chiang YL: Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 1995;55:5283-5287.
59. Xu GW, Sun ZT, Forrester K, Wang XW, Coursen J, Harris CC: Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology 1996;24:1264-1268.
60. Kanai F, Lan KH, Shiratori Y, Tanaka T, Ohashi M, Okudaira T, Yoshida Y, Wakimoto H, Hamada H, Nakabayashi H, Tamaoki T, Omata M: In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res 1997;57:461-465.
61. Rubin J, Galanis E, Pitot HC, Richardson RL, Burch PA, Charboneau JW, Reading CC, Lewis BD, Stahl S, Akporiaye ET, Harris DT: Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen. HLA-B7. Gene Ther 1997;4:419-425.